MedinCell S.A./€MEDCL
1D1W1MYTD1Y5YMAX
Capital at risk
About MedinCell S.A.
MedinCell S.A. is a pharmaceutical company focused on the development of long-acting injectable therapeutics. Operating in the healthcare industry, MedinCell specializes in drug delivery technology that combines global health needs with the potential for improved patient adherence. The company is known for its proprietary BEPO technology, which allows for controlled and sustained release of medication. Founded in 2002 and headquartered in Jacou, France, the company works on a pipeline of therapeutic solutions across various segments, including pain management, contraception, and mental health. MedinCell's strategic position is reinforced by its collaborative partnerships and its innovative approach to addressing unmet medical needs with affordable healthcare solutions.
- Ticker
- €MEDCL
- Sector
- Health
- Primary listing
- PAR
- Employees
- 141
- Headquarters
- Jacou, France
- Website
- www.medincell.com
MedinCell S.A. Metrics
BasicAdvanced
€781M
-
-€0.94
0.97
-
Price and volume
Market cap
€781M
Beta
0.97
52-week high
€39.02
52-week low
€20.32
Average daily volume
59K
Financial strength
Current ratio
4.671
Quick ratio
4.595
Long term debt to equity
17.098
Total debt to equity
23.471
Interest coverage (TTM)
-3.77%
Profitability
EBITDA (TTM)
-20.052
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-128.88%
Operating margin (TTM)
-85.44%
Effective tax rate (TTM)
0.22%
Revenue per employee (TTM)
€170,000
Management effectiveness
Return on assets (TTM)
-13.06%
Return on equity (TTM)
470.38%
Valuation
Price to revenue (TTM)
29.961
Price to book
254.77
Price to tangible book (TTM)
-1,876.56
Price to free cash flow (TTM)
-27.347
Free cash flow yield (TTM)
-3.66%
Free cash flow per share (TTM)
-0.797
Growth
Revenue change (TTM)
-12.44%
Earnings per share change (TTM)
51.05%
3-year revenue growth (CAGR)
21.14%
10-year revenue growth (CAGR)
10.09%
3-year earnings per share growth (CAGR)
-9.56%
10-year earnings per share growth (CAGR)
37.12%
Bulls say / Bears say
Successfully raised €48 million via private placement at €20.35 per share in March 2026, boosting cash runway for R&D and pipeline expansion. (Reuters)
European Investment Bank waived its right to cash-settlement of ~780,000 warrants under a €40 million facility, removing a contingent repayment obligation and enhancing long-term financial flexibility. (Reuters)
European Medicines Agency accepted Teva’s MAA for once-monthly olanzapine LAI in April 2026, clearing a key regulatory milestone for EU market entry. (Reuters)
Operational loss widened to €X million in FY 2025-26, driven by higher R&D and commercial expenses, intensifying cash burn. (Reuters)
Share price plunged 12.9% on June 17, 2026 after annual results disappointed investors, reflecting skepticism over profitability. (Reuters)
Q1 UZEDY net sales reached $63 million, up 62% year-on-year, yet remain modest relative to rising operating costs, underscoring dependence on external funding. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2026.
Upcoming events
No upcoming events
Funds containing MedinCell S.A.
AllUSDEURGBP
Fund name | Fund size | €MEDCL weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.09% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.09% |
iShares Healthcare Innovation£DRDR | £1B | 0.09% |
iShares Ageing Population€AGED | €822M | 0.08% |
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.04% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.